{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:45:07Z","timestamp":1792928707652,"version":"4.5.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"DOI":"10.1182\/bloodadvances.2025016423","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T17:40:32Z","timestamp":1754674832000},"page":"6092-6095","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed\/refractory large B-cell lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"first","affiliation":[{"name":"1Division of Cancer Medicine, Departments of Lymphoma\/Myeloma and Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"DiPersio","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Siteman Cancer Center, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Essell","sequence":"additional","affiliation":[{"name":"3Oncology Hematology Care, Inc., Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Medical Oncology, Department of Medicine, NYU Grossman School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Weill Cornell Medical College, Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-1796","authenticated-orcid":false,"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"7Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"8Research and Development, Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xu","sequence":"additional","affiliation":[{"name":"8Research and Development, Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Fanton","sequence":"additional","affiliation":[{"name":"8Research and Development, Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohail","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"8Research and Development, Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary H.","family":"Lee","sequence":"additional","affiliation":[{"name":"8Research and Development, Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Mario Q.","family":"Marcondes","sequence":"additional","affiliation":[{"name":"8Research and Development, Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"8Research and Development, Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Zalevsky","sequence":"additional","affiliation":[{"name":"8Research and Development, Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David","family":"Miklos","sequence":"additional","affiliation":[{"name":"7Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[{"name":"9Fred Hutchinson Cancer Center, The University of Washington School of Medicine, Seattle, WA"},{"name":"10University of Sydney, Camperdown, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[{"name":"11Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplant, University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"8","key":"2025120910312346200_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"26","key":"2025120910312346200_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120910312346200_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025120910312346200_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"2025120910312346200_bib5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10254","key":"2025120910312346200_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"2025120910312346200_bib7","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025120910312346200_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-140120","article-title":"High IL-15 serum concentrations are associated with response to CD19 CAR T-cell therapy and robust in vivo CAR T-cell kinetics","volume":"136","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025120910312346200_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"8047","key":"2025120910312346200_bib10","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"16","key":"2025120910312346200_bib11","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"suppl 13","key":"2025120910312346200_bib12","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1538-7445.AM2017-1603","article-title":"NKTR-255 engages the IL-15 pathway driving CD8 T-cell survival and CD8 memory T-cell proliferation [abstract]","volume":"77","author":"Kuo","year":"2017","journal-title":"Cancer Res"},{"issue":"5","key":"2025120910312346200_bib13","doi-asserted-by":"crossref","first-page":"e002024","DOI":"10.1136\/jitc-2020-002024","article-title":"NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy","volume":"9","author":"Miyazaki","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"2025120910312346200_bib14","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1182\/blood-2021-147758","article-title":"Safety, tolerability, PK\/PD and preliminary efficacy of NKTR-255, a novel IL-15 receptor agonist, in patients with relapsed\/refractory hematologic malignancies [abstract]","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2025120910312346200_bib15","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood.2024024952","article-title":"A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia","volume":"144","author":"Srinagesh","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025120910312346200_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"19","key":"2025120910312346200_bib17","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025120910312346200_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cpt.2561","article-title":"In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed\/refractory large B-cell lymphoma","volume":"112","author":"Ogasawara","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"2025120910312346200_bib19","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2025120910312346200_bib20","first-page":"581.e1","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"11","key":"2025120910312346200_bib21","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/bloodadvances.2022008697","article-title":"A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy","volume":"7","author":"Hirayama","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6092\/2443039\/blooda_adv-2025-016423-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/6092\/2443039\/blooda_adv-2025-016423-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:31:30Z","timestamp":1765294290000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/23\/6092\/546530\/NKTR-255-enhances-complete-response-following-CD19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":21,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016423","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,9]]},"published":{"date-parts":[[2025,12,1]]}}}